Background: Quality of life in prostate cancer patients with clinically localized disease has become the focus of increasing attention over the past decade. However, few instruments have been developed and validated to assess quality of life speci®cally in this patient population. Objective: The purpose of this investigation was to create a comprehensive, multi-scale quality of life instrument that can be tailored to the needs of the clinician/investigator in multiple settings. Design, subjects, and measures: Patients diagnosed with clinically localized prostate cancer were mailed a questionnaire consisting of new and previously validated quality of life items and ancillary scales. Data from returned questionnaires were analyzed and used to create a multiscale instrument that assesses the eects of treatment and disease on urinary, sexual, and bowel domains, supplemented by a scale assessing anxiety over disease course/eectiveness of treatment. The instrument was then mailed to a second sample of prostate cancer patients once and then again two weeks later to assess test±retest reliability. To assess feasibility in clinical settings, the instrument was self-administered to a third patient sample during a urology clinic visit. Results: All scales exhibited good internal consistency and test±retest reliability, convergent and discriminant validity, and signi®cant correlations with disease speci®c, generic health-related, and global measures of quality of life. Men with greater physiologic impairment reported more limitations in role activities and more bother. Scales were also able to dierentiate patients undergoing dierent therapies. All scales exhibited negligible correlations with a measure of socially desirable responding. Additionally, the instrument proved feasible when used as a self-administered questionnaire in a clinical setting. Conclusions: The current instrument possesses brief multi-item scales that can be successfully self-administered in multiple settings. The instrument is¯exible, relatively quick, psychometrically reliable and valid, and permits a more comprehensive assessment of patients' quality of life.
adjusted life years is taken into account, some classes of patients will achieve greater bene®t by foregoing aggressive treatment [9] . Because of these and related ®ndings, most clinicians and researchers advocate discussing with patients the potential impact on quality of life when making treatment decisions [10] . Fueling this recommendation is the recognition that quality of life variables can be measured in a rigorous manner [11± 14] as well as an awareness that third party payers are beginning to consider impact of treatment on quality of life when making reimbursement decisions [13] .
The physician who attempts to discuss quality of life issues with prostate cancer patients in a realistic yet reassuring way, however, is faced with a daunting task. Whereas several quality of life investigations have suggested that treatment-associated morbidity is generally well tolerated by patients [3, 5, 15±18] , agreement on this point is not universal [7, 8] . Closer examination of these studies reveals substantial dierences in patient samples and methodology, suggesting that de®ni-tive statements regarding post-treatment quality of life cannot yet be made. More importantly, although information from population-based studies of the eects of treatment is useful, most clinicians will need to be knowledgeable about the outcomes experienced by the patients speci®c to their practice to render appropriate guidance.
Without an ecient and structured means to acquire such information, physicians will be unable to collect the practices-speci®c outcomes data needed to render adequate counseling. Although most clinicians possess some knowledge of the treatment outcomes experienced by their patients, a variety of factors prohibit collection of reliable information about morbidity and the impact of morbidity on patients' quality of life, with perhaps the most critical being the lack of time imposed by the constraints of modern practice.
These problems are compounded by the lack of validated quality of life instruments speci®cally targeted at men with localized prostate cancer. Those that are available are primarily ®rst-generation instruments designed for large, survey-style research and may not be appropriate for clinical settings. For example, although existing instruments use multi-item scales to assess decrements in urinary, sexual and bowel function, the impact of these decrements on patients' quality of life is typically assessed through single-item measures of bother. Because single item measures often produce unreliable estimates and suer from lack of precision [19±21] , they may lead to faulty conclusions about the eects of disease and treatment, especially when used to monitor individual patients over time. Moreover, bother items by themselves cannot express why a given patient is experiencing psychological distress, which limits the ability of clinicians to render the most appropriate and cost-eective care.
Additionally, no instruments targeted at prostate cancer patients with localized disease currently assess anxiety over disease course and the eectiveness of treatment. Past investigations have suggested that`cancer worry' aects patients' quality of life [5] . However, the lack of a validated measure has prevented reliable assessment of cancer worry in prostate cancer patients. To what extent cancer worry is a problem in this population is currently unknown. Another concern is that items from previous scales were not tested for social desirability. Items tapping potentially sensitive topics (e.g., sexual function) may sometimes elicit overly positive responses from patients who do not wish to appear inferior or de®cient in domains they consider important [22] . This is problematic because items that elicit socially desirable responding may produce data that underestimate the impact of treatment on quality of life.
With theses issues in mind, we developed and evaluated scales for a disease-speci®c, quality of life instrument targeted at men treated for localized prostate cancer that can be used in clinical or research settings. Because a number of rigorous investigations have recently been performed in this area, we were able to draw from and build upon previous work, instead of proceeding from a vacuum.
We focused much of our eort on the creation of scales that tap important quality of life domains that previous instruments do not assess, or assess only in a limited fashion. However, because some of the current instrument's scales overlap conceptually with previously validated scales, we strove to create measures that correlated with related measures whenever possible. We also designed the current instrument so that it could be tailored to the needs of investigators. With the current instrument, researchers and clinicians can decide on a case-bycase basis which scales to use and whether to pair scales with additional measures, such as more generic health-related quality of life scales.
Method

Sample
Three samples were used to create and evaluate the instrument. The ®rst sample, hereafter referred to as the primary sample, consisted of 300 prostate cancer patients randomly selected from a larger, national sample of patients who had been tracked longitudinally after undergoing prostate speci®c antigen screenings during Prostate Cancer Awareness Week from 1991 to 1994. Details concerning diagnosis and staging have been described elsewhere [23] . All eligible patients from the larger sample had received a diagnosis of localized prostate cancer since their initial screening. Additionally, a majority of patients in the larger sample had recently participated in a telephone poll commissioned by the American Urological Association. During the poll, patients were informed they would be contacted by mail and asked to participate in an additional study focusing on quality of life. A second sample was used to evaluate the test±retest reliability of the instrument. The 200 patients contacted for participation in the test±retest sample were identi®ed using the urology clinic records of a large hospital in the southeast US. All patients in the test±retest sample had been diagnosed with and treated for clinically localized prostate cancer. A third group of patients, consisting of a convenience sample of 40 patients attending a urology clinic at a large, urban hospital in the southern US, was used to determine the instrument's feasibility in a clinical setting. The patients self-administered the instrument while waiting for an appointment with a urologist.
Data collection
For the primary sample, an introductory letter outlining the goals of the study was ®rst sent out to patients, after which each patient received a mailed questionnaire packet with a cover letter assuring anonymity and $5.00 which patients were free to keep regardless of whether they returned the questionnaire. Following a four week interval, any patients who had not returned the questionnaire were sent another copy and asked to return it within two weeks time. No further attempts were made to secure responses after this second attempt in order to avoid placing undo burden on patients. Procedures for the test±retest sample paralleled the ones used for the original sample, with the addition of a second mailing occurring two weeks after the ®rst questionnaire was returned. Participants in the clinic sample were approached by a research assistant and asked to complete a questionnaire.
Instrument development and conceptual framework
Because the term``quality of life'' when used in association with health-related matters is often ill-de®ned [24] , we attempted to construct a multiscale quality of life instrument that could serve diverse purposes. In keeping with prior work [3, 5] , items were ®rst chosen that would permit assessment of two conceptually distinct domains: (1) the degree of impairment in physiologic function associated with treatment complications and (2) how much bother patients experience as a result of impairments in physiologic function. In this context, bother refers to how much psychological distress and unhappiness patients experience. An example item from the former domain is``Over the past four weeks, how often have you leaked urine?'' An example item from the latter domain is``Over the past four weeks, how often has your urinary function made it dicult to enjoy your life? '' In order to increase the instrument's ability to explain how impairments in function are related to bother, items tapping a third, conceptually-distinct domain were also developed. These items assess to what extent impairments in physiologic function limit role activities, speci®cally activities related to social, physical, occupational, sexual, and relationship functioning. A sample item from this domain is``During the past four weeks, how much did your urinary function OR your concerns and feelings about your urinary function limit your social activities?''
Based on previous investigations [3, 5] and pilot work, we applied this conceptual approach to the organ systems most often aected by treatment for localized prostate cancer: urinary, sexual and bowel. For each organ system we developed three scales, one assessing physiologic impairment, one assessing limitations in role activities and one assessing bother. Additionally, we developed a separate scale to assess cancer worry, the amount of worry and concern patients experience over disease course and perceived eectiveness of treatment. Table 1 describes the 10 content areas for which scales were developed.
For each of the 10 content areas we identi®ed a broad range of test items from past instruments [3, 5, 25] and from consultations with health care professionals, including two urologists, an internist and a psychologist. The test items were ®rst mailed to a sample of 20 patients treated for clinically localized prostate cancer who were asked to provide feedback. On the basis of this feedback, additional items were constructed and some of the phrasings of previously generated items were modi®ed. This process produced 120 Likert-type test items. The items were targeted at the 8th grade reading level or lower as assessed by the FleschKincaid Grade Level score, a standard feature of most word-processing packages. However, a few speci®c words (e.g., recurring) may require a higher level of reading ability. These items and some additional measures were administered through a mail-out survey to the primary patient sample described previously. To reduce potential order eects, the urinary, sexual and bowel sections were permuted, so that six dierent versions of the questionnaire were mailed.
Validation measures
To validate the scales derived from the test items, several other previously validated measures and additional items were administered simultaneously with the test items, including the Prostate Cancer Index (PCI) [5] , a health-related quality of life measure targeted at prostate cancer patients, the Medical Outcomes Study 36-item Short Form Health Survey (SF-36) [26] , one of the most commonly used measures of generic health-related quality of life, the Positive and Negative Aect Schedule (PANAS) [27] , a 20-item, Likert-type scale that separately assesses levels of positive and negative emotion and can be used as a measure of global quality of life, and the Satisfaction with Life Scale [28] , a global quality of life scale. These quality of life measures were speci®-cally chosen because they range from the speci®c (e.g., PCI) to the global (e.g., PANAS). This approach permits validation along a proximal-distal continum [29] . If the instrument is valid, its scales should correlate to a greater degree with other disease-speci®c measures and less so (although still signi®cantly) with more global measures of quality of life. Additionally, the Impression Management Scale of the Balanced Inventory of Desirable Responding [22] was included to assess whether any items elicited socially desirable responding. Several open-ended questions were also included to solicit patients' feedback regarding the comprehensibility and relevance of test items. Additional items were included to assess demographics, comorbidities and treatment history.
Analysis
On the basis of psychometric and clinical considerations, the test pool of 120 items was reduced to 52 ®nal items, with each of the 10 scales containing between 4 and 7 items. Speci®cally, items exhibiting skewed response distributions were ®rst eliminated from future consideration. Within each of the urinary, sexual and bowel sections, exploratory factor analysis [30] was then used to select items for the function and bother scales. After item selection for the function and bother scales, items addressing limitations in role activities were chosen on the basis of clinical considerations and face validity. Item±total correlations and impact on Cronbach's a were used for additional item paring for all scales. Following the determination of scale items, linear transformations were used to produce scale scores ranging from 0 to 100. For all scales, higher scores denote better outcomes. Item stems are listed in the Appendix. From a psychometric perspective, scales should possess high levels of reliability and construct validity, especially when used for clinical purposes [19, 26] . Internal consistency reliability was assessed by computing Cronbach's coecient a for each scale [31] . Because respondents in the primary sample were guaranteed anonymity (i.e., all identifying information was removed from returned questionnaires), it was not possible to assess test±retest reliability in the original data set.
To evaluate test±retest reliability, were recruited an additional sample and mailed them the 52-item questionnaire once at wave 1 and then again two weeks later at wave 2. A question asking respondents to report the time needed to complete the questionnaire packet, several demographics items and some other exploratory measures not relevant to the current investigation were included in the wave 1 questionnaire. Test±retest reliability was assessed via product moment and intra-class correlations [32] .
To assess construct validity, several methods were employed.
Convergent/discriminant validity was assessed based on the product moment correlations among the 10 scales. If the scales are valid, scales within an organ system should tend to correlate more highly than scales from dierent organ systems. Concurrent validity, sometimes referred to as`k nown groups validity,'' indicates the ability of a scale to discriminate between groups that are known or believed to dier [34] . Concurrent validity was assessed in two ways. To determine whether scales were sensitive to dierences in patients with more vs. less physiologic dysfunction, product moment correlations were computed between function and daily limitations and bother scales within each organ group. To determine if the scales could dierentiate surgical, radiation and watchful waiting patients, urinary, sexual and bowel function scores were each subjected to a one-way analysis of covariance (ANCOVA) using treatment type as the independent variable and age, number of comorbidities and time since diagnosis as covariates. Planned comparisons, conducted on the basis of previous ®ndings [4, 5] , were used to assess speci®c dierences among the treatment means, with the expectation that surgical patients would be more likely to show impaired urinary and sexual function and radiation patients would be more likely to show bowel function impairments. To assess the eciency of the function scales' ability to detect dierences across groups, relative eciency ratios were computed [35] . Ratios were calculated by taking the F statistic associated with each function scale over the F statistic derived from the same analysis using the relevant PCI scale. Ratios greater (or less) than one indicate that the current instrument is a more (or less) ecient measure of between group dierences than the PCI. The PCI was used as a standard of comparison because it possesses physiologic function scales similar to those of the current instrument.
Criterion validity was assessed by computing product moment correlations between scales and previously validated measures of quality of life. To assess whether the scale items of the current instrument tended to evoke biased responses from participants because of social desirability concerns, product moment correlations between the ten scales and a measure of impression management were calculated. Feasibility was assessed by examining how long respondents in the test±retest sample took to complete the questionnaire and by assessing participation rate and number of items left blank in the urology clinic sample. Bowel and cancer worry scales were not administered to the clinic sample because none of the sample had undergone radiation and because some of the sample did not have prostate cancer.
Results
Participants
Response rate in the primary sample was 90%. The data from 5 patients who reported they did not have prostrate cancer, 6 patients who failed to complete the majority of the questionnaire, 45 patients who reported treatment indicative of metastatic disease (e.g., orchiectomy) and 1 patient who reported receiving cryotherapy, were excluded from analysis. Scale scores, self-reported treatment history and other characteristics of the remaining 212 respondents are presented in Tables 2 and 3 . The participant sample spanned the three major forms of treatment (e.g., radical prostatectomy, radiation and watchful waiting), although more patients reported having undergone surgery than radiation or watchful waiting, and about 9% reported having received surgery and radiation. Mean age was about 68, and mean time since diagnosis was about 4 years. Most of the sample classi®ed themselves as white/caucasian and currently married. The patient sample used for the test±retest study was similar to the primary sample, except that average time since diagnosis was 3 years, mean age was about 65, the racial composition was 14% black and 86% white, and the vast majority had been treated surgically. Eight-two percent of the patient sample responded to both waves of the test±retest administration. Participants in the clinic sample were on average 63 years old, and the majority classi®ed themselves as white/caucasian and currently married. All of the clinic patients who were asked to complete the instrument did so. Internal consistency reliability
As reported in Table 4 , scale a's in the sample tended to be high, with most above 0.80. These a's suggest that the scales are reliable and unidimensional. The internal consistency reliability of the scales is further supported by the a's from the test± retest sample. As shown in Table 4 , these coecients parallel and at times exceed the coecients from the original sample.
Test±retest reliability
As depicted in Table 4 , the 10 scales exhibit levels of test±retest reliability that are comparable to or better than similar health related quality of life scales. Notably, this holds true whether one examines the product-moment or intra-class correlations.
Convergent/discriminant validity Table 5 presents the product-moment correlation matrix of the 10 scales from the validation sample.
As can be seen from the matrix, scales within each organ system area tend to converge (i.e., correlate more) with one another, whereas scales belonging to dierent content areas tend to diverge (i.e., correlate less) from one another, suggesting that the 10 scales possess good convergent and discriminant validity.
Concurrent validity
The positive correlations in bold in Table 5 also indicate that patients who experience greater decrements in function also show greater limitations in role activities and increased levels of bother, compared to patients with less decrement in function, who report experiencing fewer limitations and less bother. Notably, this holds true whether urinary-, sexual-or bowel-related variables are being assessed.
To provide further evidence of concurrent validity, the physiologic dysfunction scores of those who had undergone surgery, radiation or watchful Theoretical range of all scales is 0±100 with higher numbers denoting better outcomes. The Cronbach's a listed for the test±retest sample is the average of the wave 1 a and wave 2 a for each scale. The test±retest statistic is the product-moment correlation coecient between wave 1 scores and wave 2 scores for each scale. The intra-class statistic is the intra-class correlation coecient between wave 1 scores and wave 2 scores for each scale.
waiting were also compared using one-way AN-COVA. As predicted, surgical patients exhibited more urinary and sexual impairment and radiation patients more bowel impairment as depicted in Table 6 . The relative eciency statistics suggest that two of the three function scales may oer more ecient measures of physiologic function than the PCI's function scales and would thus require fewer subjects to detect a given eect size.
Criterion validity
As Tables 7 and 8 indicate, all 10 scales correlated as predicted with other measures of health-related and global quality of life. At the disease-speci®c level, the function scales correlated highly with the PCI function scales for each organ system as depicted in Table 7 . Similarly, the bother scales correlated highly with the PCI's single-item measures of bother. The limitations in role activities scales correlated only moderately with the PCI scales, suggesting that they tap constructs not assessed by the PCI. In general, however, the high correlations between the current instrument and the PCI suggest good criterion validity.
The scales of the current instrument are also associated with those of the SF-36, a global measure of health status. The 80 possible correlations between the current instrument's 10 scales and the 8 scales of the SF-36 were all in the predicted direction and all but 10 were statistically signi®cant, with the average correlation coecient being 0.25. The pattern of correlations tended to support the validity of the current instrument's scales. For example, the cancer worry scale correlated most highly with the Mental Health (r = 0.33) and Role Functioning ± Emotional scales of the SF-36 (r = 0.30), which suggests that this scale is indeed tapping emotional distress.
The scales of the current instrument also correlated with global quality of life measures, speci®cally the PANAS-N, the selection of the PANAS that assesses negative aect, and the Satisfaction with Life Scale as shown in Table 8 . Speci®cally, the role limitations and bother scales all correlated signi®cantly with the Satisfaction with Life Scale and the PANAS-N.
Evaluation of impression management
Only 2 of the 10 correlations between the instrument's scales and the impression management scale were signi®cant or marginally signi®cant, and both of these were small in magnitude (for urinary function, r = 0.13, p < 0.06; for sexual bother, r = 0.17, p < 0.02). These ®ndings suggest that the items used in the current instrument generally do not evoke social desirability concerns. Respondents are not knowingly misrepresenting themselves as better o than they really are.
Feasibility
Average time to complete the wave 1 questionnaire packet administered to the test±retest sample, which consisted of the 52-item instrument plus 54 additional items, was 29.48 min (SD = 19.78). This ®nding suggests that the instrument by itself would take about 15 min to complete. Additionally, when the urinary and sexual scales were administered to the urology clinic sample, no patient refused to complete the questionnaire and no items were left blank. The current instrument possesses many of the properties that would enable it to perform successfully in this capacity. For example, the majority of the scales possess alphas higher than 0.80, which indicate the scales produce reliable measurements of their respective constructs. However, it is also true that the a's for the sexual role limitations in the primary sample and bowel function scale in the primary and test±retest samples are slightly lower than would be preferred, although still in the acceptable range. In the case of the sexual role limitations scales, this is not necessarily worrisome as sexual function and concerns about sexual function are unlikely to limit all role activities similarly (e.g., impairments in sexual function are likely to limit relationships activities much more than physical activities) and thus an extremely high a for this scale would be surprising. The a's for the bowel function scale, however, may indicate that this scale needs further re®nement.
In addition to high levels of internal consistency reliability, the scales also possess high levels of test±retest reliability, as indicated by both the product-moment and the intra-class correlations. The two types of correlations used to examine test±retest reliability did not dier much in the current investigation because the average dierence between wave 1 and wave 2 scores was very small [32] , ranging from 0 to 2.57 points across the 10 scales. The nearly equivalent product-moment and intra-class correlations suggest that wave 1 and wave 2 scores generally did not dier systematically, which further underscores the psychometric integrity of the instrument. High test± retest reliability is important because measures that produce scores that¯uctuate over time may obscure clinically important changes in patients' quality of life. Thus, instruments intended for use in a clinical setting to monitor an individual patients' progress are generally required to produce relatively stable scores in the absence of true change [33] .
Most of the scales of the current instrument performed well in this regard, although the test± retest correlations for the bowel scales were lower than the urinary or sexual scales. Similarly, the test±retest coecient for the cancer worry scale was somewhat lower than the others. This may indicate a de®ciency in the scale, but it may also re¯ect the¯uctuating nature of cancer worry in this population relative to the other constructs assessed by the PC-QoL. Cancer worry is likely to wax and wane according to a variety of situational factors, such as whether a prostate cancer story has recently appeared in the media or whether a PSA test is approaching or has just passed. Thus, it would surprising if the cancer worry scale exhibited extremely high levels of test±retest reliability due to the labile nature of the variable it measures.
In terms of validity, the instrument also performed well. All scales exhibited good convergent/ discriminant validity. For example, urinary function correlated more highly with urinary role limitations and urinary bother than with any other scales. The same holds true for the other organ systems, as would be expected if the scales were valid. The results of the current study also indicate that the scales possess good concurrent validity. The ability to discriminate among groups is often a required characteristic of measures used in clinical trials and other research-related activities when the goal is to determine whether one group experiences better or worse outcomes than another. As evidenced by the data in Tables 5 and 6 , the bother and limitations scales are sensitive to dierences in amount of physiologic dysfunction and the function scales can discriminate among treatment groups (e.g., patients treated surgically exhibit worse urinary and sexual function than radiation or watchful waiting patients). It is important to note, however, that this latter ®nding should be generalized with caution because the patient sample used in this investigation was not recruited to assess dierences across treatment groups per se (e.g., baseline functioning prior to treatment is unknown and therefore could not be incorporated into the relevant analyses).
In terms of criterion validity, the scales performed well as indicated by the high correlations with their respective counterparts in the PCI. The relatively high correlations are not surprising given that both instruments are disease-speci®c and that several of the PCI items are used in modi®ed form in the scales of the current instrument (e.g., the PCI's single item bother measures are contained in the current instrument's bother scales). The instrument's criterion validity is also supported by the pattern of correlations with the Satisfaction with Life Scale and the PANAS. The lack of association with the PANAS-P, the section of the PANAS that assesses positive aect, is consistent with those of past investigations, which tend to show that health and health concerns are more strongly associated with negative than with positive aect [36] . Of additional importance is the signi®cant correlation between the PANAS-N and the cancer worry scale, which indicates that the more concerned patients were over disease course/ treatment eectiveness, the more negative emotions they experienced. This association suggests that this scale does not indeed tap anxiety, worry and related negative emotions, thereby supporting the scale's validity.
Of note, the overall validity of the instrument is supported by the increasing associations between its scales and other quality of life instruments as those other measures range from the distal to the proximal [29] . This pattern supports the instrument's validity. Because the current instrument measures eects speci®c to prostate cancer and its treatment, it should correlate most highly with similar disease-speci®c measures like the PCI, but less so with measures that are not disease-speci®c, like the SF-36 and the PANAS, because many factors other than prostate cancer aect generic health-related and global quality of life.
However, most of the scales of the current instrument still correlate signi®cantly with the global quality of life measures used in this study. This is an important ®nding because it demonstrates that the eects of treatment on prostate cancer patients are not trivial. Despite the great variety of factors that contribute to global quality of life (e.g., relationship quality, personality, income level, job satisfaction, overall health, etc.), the eects of treatment for prostate cancer are of sucient magnitude to be measurable at the most general level, even in a patient sample that has had four years on average to adapt to treatment-related morbidity.
Taken together, the results suggest that the current instrument possesses many of the properties necessary for use as an evaluative/monitoring instrument in clinical settings or as a discriminative instrument in research settings. The instrument also extends previous work in several ways. First, the current instrument oers multi-item scales assessing bother. This addition is important because most earlier prostate cancer investigations examining bother and related variables have used single item measures [3, 5] , which typically lack precision and do not provide reliable measurements of a construct [19±21, 35] . This is potentially problematic because the results of single-item measures from past studies are often used as support for the proposition that prostate cancer patients adapt well to complications of aggressive therapy. Given the de®ciencies inherent in oneitem measures, this conclusion may or may not be warranted.
For example, as depicted in Table 9 , 24% of respondents endorsed the`no problem' response to the question``How big a problem has your sexual function been for you over the last four weeks?'' All of these patients would have received a perfect score of 100 if this single item had been used to assess bother. However, these same patients received a mean score of 83 (SD = 18) when their multi-item score was examined, with multi-item scores in this group ranging anywhere from 36 to 100. In fact, only 6.3% of patients who would have received a 100 using the single-item would have also received a 100 using the multi-item scale. These patients appear to be experiencing a wide range of distress and bother related to sexual function that is not tapped by the syntax of a single item. The same holds true at every response level of the single-item measure. Even when the single-item score is similar to the average multiitem score, there is still considerable variation evident in the multi-item scores of patients. Notably, this pattern recurs when single and multi-item measures of urinary and bowel bother are compared, albeit to a lesser extent. This suggests that multiple items are necessary to assess bother in a rigorous manner, especially in cases where an individual patient's score would be used as a basis for clinical decision making. As demonstrated by Table 9 , using single items as a basis for classifying individual patients will often lead to incorrect categorizations.
The importance of assessing bother accurately is highlighted by the patterns of correlations reported in Table 8 , which slow that bother tends to be more consistently and highly correlated with other measures of global quality of life than the function and limitations scales, particularly in the urinary domain. These ®ndings suggest that valid and reliable bother scales are necessary to assess the eect of treatment on patients' quality of life.
A further bene®t oered by the current instrument is the cancer worry scale, which uses items that are applicable to prostate cancer patients undergoing aggressive therapy as well as those who have chosen watchful waiting. As suggested by past research [5] and by the signi®cant correlations of this scale with the other quality of life measures in the current study, cancer worry may aect prostate cancer patients' quality of life. Thus, it is important to be able measure this domain in a valid and reliable manner. As suggested by the signi®cant correlations between this scale and the PANAS-N and by its relatively high Cronbach's a, the 4-item cancer worry scale oers a quick and valid way to assess patient worry and concern in this domain.
The development and validation of the limitations in role activities scales for each organ system also dierentiates the current instrument from previous eorts. These scales provide a relatively quick means by which patients can communicate why they are experiencing diculties tolerating treatment-related morbidity, which in turn should facilitate the provision of the most appropriate and cost-eective follow-up care. For example, if a 94 (6) 81 (8) 68 (9) 46 (14) 33 (10 Single-item score refers to the bother score patients would have received based on their response to the single item. Mean multi-item score refers to the average bother score received by patient groups endorsing each response option of the single item. Min. and max. refer to the minimum and maximum multi-item score received by each patient group.
patient reports signi®cant bother due to high levels of incontinence following radical prostatectomy, clamps or pads may be sucient to provide relief if bother is due to incontinence-induced limitations in physical activities like playing sports or doing chores. However, if the patient's emotional distress is due to incontinence-induced limitations in sexual activities, then further surgery or psychological counseling may provide the only means to relieve distress. Another bene®t oered by the current instrument is the use of scales that were validated against a measure of impression management. The lack of or low correlations between the 10 scales and the impression management measure suggest that social desirability concerns did not cause patients to knowingly portray themselves as better o than they really were, even in regard to potentially sensitive areas like sexual function. These ®ndings indicate that the current instrument elicits truthful reports from patients regarding the eects of treatment on quality of life.
Some limitations of the current investigation should be noted. The ®rst is that the psychometric properties of the current instrument require further assessment in additional samples. It is possible the instrument would perform more poorly on patient samples that diered on important attributes (e.g., socioeconomic status). The second is that men who initially chose to undergo PSA screening during Prostate Cancer Awareness Week may experience dierent outcomes than other prostate cancer patients. However, the primary sample demonstrated a relatively large amount of variability in most outcomes, suggesting that the sample was adequate in this respect. Of greater concern was the racial composition of the primary sample, which was composed mostly of white patients. Further research is needed to verify the validity, reliability and feasibility of the instrument in non-white patients.
Additionally, because most patients diagnosed with clinically localized prostate cancer have a spouse or romantic partner, the current instrument employs several items that are targeted at men with partners (e.g., how often did you initiate sexual activities with a spouse or partner?). Thus, the instrument may provide less precise scores of men without partners. However, all items possess response options that can be endorsed by men without partners and all scales contain items that do not involve partners, which should tend to mitigate any eects of partner status. Finally, although the majority of the scale a's approached 0.90, which is the criterion typically required of scales used to monitor and evaluate individual patients [19] , some of the scales did not meet this standard. This suggests that until further experience with these measures is obtained, use of some of the current instrument's scales to monitor individuals (as opposed to groups) should be performed with caution.
A ®nal caveat concerning the length of the PCQoL should be made before concluding this section. The PC-QoL oers several enhancements over pre-existing measures, but it is also by necessity longer than similar instruments and may be more burdensome. Although investigators have the option of foregoing those PC-QoL scales that are not relevant to their needs, they should carefully consider the strengths and weaknesses of all available measures when choosing an instrument.
However, none of these limitations substantially aects the main ®ndings of this study, which provide evidence of the current instrument's reliability, validity and feasibility. To increase further the instrument's utility, continual re®nement is underway and computer-administered versions are currently being piloted for use over the Internet. This process will make interpretable feedback quickly accessible to clinicians/ investigators interested in using the instrument as a tool to assess outcomes and improve quality of care.
Conclusion
Currently, few validated instruments exist to assess how prostate cancer patients with localized disease are aected by undergoing or foregoing treatment. Moreover, there is often great disparity in how quality of life is assessed, which has the eect of limiting comparisons across studies. By embracing and building upon elements of past work, we have created a multi-scale, quality of life instrument that can be used in multiple settings and can be tailored to the individual needs of the clinician or investigator. 
